Validation of thermal dynamics during Hyperthermic IntraPEritoneal Chemotherapy simulations using a 3D-printed phantom.
cancer biology
computational fluid dynamics (CFD)
computational modeling
hyperthermic intrapertioneal chemotherapy (HIPEC)
translational research
treatment planning software
validation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
11
2022
accepted:
24
01
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
CytoReductive Surgery (CRS) followed by Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) is an often used strategy in treating patients diagnosed with peritoneal metastasis (PM) originating from various origins such as gastric, colorectal and ovarian. During HIPEC treatments, a heated chemotherapeutic solution is circulated through the abdomen using several inflow and outflow catheters. Due to the complex geometry and large peritoneal volume, thermal heterogeneities can occur resulting in an unequal treatment of the peritoneal surface. This can increase the risk of recurrent disease after treatment. The OpenFoam-based treatment planning software that we developed can help understand and map these heterogeneities. In this study, we validated the thermal module of the treatment planning software with an anatomically correct 3D-printed phantom of a female peritoneum. This phantom is used in an experimental HIPEC setup in which we varied catheter positions, flow rate and inflow temperatures. In total, we considered 7 different cases. We measured the thermal distribution in 9 different regions with a total of 63 measurement points. The duration of the experiment was 30 minutes, with measurement intervals of 5 seconds. Experimental data were compared to simulated thermal distributions to determine the accuracy of the software. The thermal distribution per region compared well with the simulated temperature ranges. For all cases, the absolute error was well below 0.5°C near steady-state situations and around 0.5°C, for the entire duration of the experiment. Considering clinical data, an accuracy below 0.5°C is adequate to provide estimates of variations in local treatment temperatures and to help optimize HIPEC treatments.
Identifiants
pubmed: 36865797
doi: 10.3389/fonc.2023.1102242
pmc: PMC9971922
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1102242Informations de copyright
Copyright © 2023 Löke, Kok, Helderman, Franken, Oei, Tuynman, Zweije, Sijbrands, Tanis and Crezee.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Cancer. 2014 Feb 1;134(3):622-8
pubmed: 23832847
Lancet Oncol. 2021 Feb;22(2):256-266
pubmed: 33476595
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Cancer Biol Ther. 2020 Aug 2;21(8):726-732
pubmed: 32644887
Cancers (Basel). 2020 Nov 26;12(12):
pubmed: 33255921
Front Oncol. 2021 Aug 06;11:674915
pubmed: 34422631
Cells. 2020 Jul 25;9(8):
pubmed: 32722384
Med Phys. 2010 Sep;37(9):4902-15
pubmed: 20964209
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641919
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Eur J Surg Oncol. 2013 Jul;39(7):754-9
pubmed: 22878060
Rev Col Bras Cir. 2016 Dec;43(6):476-479
pubmed: 28273222
Cancer Res. 2007 Aug 15;67(16):7646-53
pubmed: 17699769
Int J Surg. 2015 Nov;23(Pt A):181-5
pubmed: 26361862
Int J Hyperthermia. 2021;38(1):38-54
pubmed: 33487083
Drug Deliv. 2021 Dec;28(1):145-161
pubmed: 33427507
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S758-65
pubmed: 26350370
Acta Radiol Oncol. 1984;23(2-3):135-9
pubmed: 6331081
Int J Hyperthermia. 2015 Jun;31(4):396-402
pubmed: 25707816